drugset / Trial / NCT04947033
A Study Evaluating TJ210001 in the Treatment of Subjects With Advanced Solid Tumors
NaSingle-groupOpen-labelTreatment
Summary
A phase I clinical study evaluating TJ210001 in the treatment of subjects with advanced solid tumors
Timeline
- Start
- 2023-12-31
- Primary completion
- 2024-12-31
- Completion
- 2025-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | IZASTOBART | Monoclonal antibody | 0.3 mg/kg | — |
| Subject | IZASTOBART | Monoclonal antibody | 1 mg/kg | — |
| Subject | IZASTOBART | Monoclonal antibody | 3 mg/kg | — |
| Subject | IZASTOBART | Monoclonal antibody | 10 mg/kg | — |
| Subject | IZASTOBART | Monoclonal antibody | 15 mg/kg | — |